Hormonal
S-309309, a novel oral inhibitor of monoacylglycerol O-acyltransferase 2 (MGAT2), demonstrates acceptable safety and tolerability in healthy adults with or without obesity, with no clinically meaningful differences in pharmacokinetics between obese and non-obese individuals.
S-309309 is an experimental oral medication that inhibits MGAT2 to potentially aid weight management. Early trials show it is safe and well-tolerated in both obese and non-obese adults, with no significant drug interactions or cardiac effects observed at tested doses. It is not yet approved for general use.
S-309309 demonstrated acceptable safety and tolerability unlike diacylglycerol transferase 1 inhibitors and lipase inhibitors. S-309309 exhibited a favorable pharmacokinetic profile, and its absorption remained unaffected by food intake. S-309309 did not show any drug interaction with midazolam.
Why this rating
Phase I RCT, double-blind, placebo-controlled, but small sample size (N=74) and short duration.
Source
Safety, Tolerability, and Pharmacokinetics of a Novel Anti-obesity Agent, S-309309, in Healthy Adults with or Without Obesity
Tôru Ishibashi et al. · Clinical Drug Investigation · 2025
DOI 10.1007/s40261-024-01418-3
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →